World Wires · story 9602 · unverified · 1 source(s)

Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy

Data from BASECAMP expected in Q1 2027 Data from BASECAMP expected in Q1 2027

Open in the desk

Coverage

• Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy GlobeNewswire: public companies · tier D · clear net · 2026-09-30 11:00 UTC

What this site indexes